Bringing our test to healthcare providers and patients
The PATHFINDER Study was a prospective, interventional, multi-center study evaluating the implementation of an earlier version of Galleri® in clinical practice. This was the first time our test had been used to return results to healthcare providers to help guide appropriate diagnostic workups, and evaluate how these test results affect diagnostic and care pathways in a screening population.
The study enrolled approximately 6,600 participants, who were followed for 12 months from the time of their enrollment. Participants included men and women aged 50 years and older who were recruited into two cohorts, those with additional cancer risk and those without additional cancer risk.
A prespecified reanalysis of blood samples was completed with the Galleri test to compare to the early version of the test. Cancer status was assessed at 12 months to determine whether or not a patient was diagnosed with cancer after taking the Galleri test.
Thank you for your contribution
GRAIL and its collaborators would like to extend a big thank you to all the participants who contributed to the PATHFINDER Study.